Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN inact mut |
| Therapy | Copanlisib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN inact mut | Advanced Solid Tumor | no benefit | Copanlisib | Phase II | Actionable | In a Phase II trial (NCI-MATCH subprotocol Z1H), Aliqopa (copanlisib) treatment demonstrated limited efficacy in patients with advanced solid tumors harboring PTEN inactivating mutations, with an objective response rate of 3.4% (1/29, 1 partial response in a patient with endometrioid endometrial adenocarcinoma), stable disease in 28% (8/29) of patients, median progression-free survival (PFS) of 1.8 mo, 6-mo PFS rate of 15.4%, and median overall survival of 9.0 mo (PMID: 39913886; NCT02465060). | 39913886 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39913886) | Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H. | Full reference... |